Suppr超能文献

[铁过载的诊断与治疗]

[Diagnosis and treatment of iron overload].

作者信息

Ruivard M, Lobbes H

机构信息

Service médecine Interne, CHU de Clermont-Ferrand, CHU d'Estaing, 63003 Clermont-Ferrand, France; UMR 6602 UCA/CNRS/SIGMA, thérapies guidées par l'image (TGI), université Clermont Auvergne, 63000 Clermont-Ferrand, France.

出版信息

Rev Med Interne. 2023 Dec;44(12):656-661. doi: 10.1016/j.revmed.2023.07.002. Epub 2023 Jul 26.

Abstract

Etiological investigation of hyperferritinemia includes a full clinical examination, with the measurement of waist circumference, and simple biological tests including transferrin saturation. The classification between hyperferritinemia without iron overload (inflammation, excessive alcohol intake, cytolysis, L-ferritin mutation) or with iron overload is then relatively easy. Dysmetabolic iron overload syndrome is the most common iron overload disease and is defined by an unexplained serum ferritin level elevation associated with various metabolic syndrome criteria and mild hepatic iron content increase assessed by magnetic resonance imaging. Bloodlettings are often poorly tolerated without clear benefit. Type 1 genetic hemochromatosis (homozygous C282Y mutation on the HFE gene) leads to iron accumulation through an increase of dietary iron absorption due to hypohepcidinemia. More than 95% of hemochromatosis are type 1 hemochromatosis but the phenotypic expression is highly variable. Elastography is recommended to identify advanced hepatic fibrosis when serum ferritin exceeds 1000μg/L. Life expectancy is normal when bloodlettings are started early. Ferroportin gene mutation is an autosomal dominant disease with generally moderate iron overload. Chelators are used in iron overload associated with anaemia (myelodysplastic syndromes or transfusion-dependent thalassemia). Chelation is initiated when hepatic iron content exceeds 120μmol/g. Deferasirox is often used as first-line therapy, but deferiprone may be of interest despite haematological toxicity (neutropenia). Deferoxamine (parenteral route) is the treatment of choice for severe iron overload or emergency conditions.

摘要

高铁蛋白血症的病因学调查包括全面的临床检查,测量腰围,以及进行包括转铁蛋白饱和度在内的简单生物学检测。然后,区分无铁过载的高铁蛋白血症(炎症、过量饮酒、细胞溶解、L-铁蛋白突变)或有铁过载的情况相对容易。代谢性铁过载综合征是最常见的铁过载疾病,其定义为血清铁蛋白水平不明原因升高,伴有各种代谢综合征标准,以及通过磁共振成像评估的轻度肝脏铁含量增加。放血疗法通常耐受性差且益处不明确。1型遗传性血色素沉着症(HFE基因上的纯合子C282Y突变)由于低铁调素血症导致膳食铁吸收增加,从而引起铁蓄积。超过95%的血色素沉着症为1型血色素沉着症,但其表型表达高度可变。当血清铁蛋白超过1000μg/L时,建议使用弹性成像来识别晚期肝纤维化。早期开始放血疗法时,预期寿命正常。铁转运蛋白基因突变是一种常染色体显性疾病,通常铁过载程度中等。螯合剂用于与贫血相关的铁过载(骨髓增生异常综合征或依赖输血的地中海贫血)。当肝脏铁含量超过120μmol/g时开始螯合治疗。地拉罗司通常用作一线治疗,但尽管有血液学毒性(中性粒细胞减少),去铁酮可能也有应用价值。去铁胺(胃肠外途径)是重度铁过载或紧急情况的首选治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验